Proteomics (ASX:PIQ) blood test reveals potential in oesophageal cancer detection

Proteomics International's new blood test, PromarkerEso, has effectively identified oesophageal cancer. 

The test provided an 89% accuracy in cancer detection and 92% in non-cancer cases.

It also targets oesophageal adenocarcinoma and Barrett's oesophagus, a pre-malignant condition linked to chronic acid reflux.

The results were presented at the 19th ISDE World Congress for Esophageal Diseases and will contribute to validating the test's prototype.